EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways

Michael B. Murphy, Laura Vitale, Shukai Xia, Zeyu Peng, Thomas O’Neill, Jay Lillquist, Anna Wasiuk, Jeff Weidlick, Jenifer Widger, Laura Mills-Chen, Andrea Crocker, Colleen Patterson und 10 weitere

Immuno · 07.07.2023 · 3 (3) · 273-288

DOI: 10.3390/immuno3030018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno, online erschienen am 07.07.2023. Verfasst von Michael B. Murphy und 21 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celldex Therapeutics, Inc..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin-like transcript 4 (ILT4) is an immunosuppressive molecule predominantly expressed on myeloid cells. Recent studies combining ILT4 suppression with programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade have shown promising signs of activity in immune checkpoint inhibitor refractory patients. We theorized that coupling ILT4 and PD-1/PD-L1 blockade in a bispecific antibody (bsAb) may provide greater immune activating properties than combining the individual mAbs due to enhanced bridging of APCs to T cells. To test this approach, we developed CDX-585, a tetravalent ILT4xPD-1 IgG1-scFv bsAb from novel PD-1 and ILT-4 mAbs. CDX-585 is a potent antagonist of both PD-1 and ILT4. CDX-585 promotes M1 macrophage polarization and enhances pro-inflammatory cytokine secretion in response to lipopolysaccharide or CD40 agonist mAb treatment. In mixed lymphocyte reaction (MLR) assays, CDX-585 is more potent than the combination of parental antibodies. In a humanized NCG mouse SK-MEL-5 tumor model, CDX-585 exhibits greater antitumor activity than the combination of parental mAbs. A pilot study of CDX-585 in cynomolgus macaques confirmed a mAb-like pharmacokinetic profile without noted toxicities. These studies demonstrate that CDX-585 effectively combines ILT4 and the PD-1 blockade into one molecule that is more potent than the combination of the parental antibodies, providing the rationale to advance this bsAb into clinical studies.

Förderung

  • Celldex Therapeutics, Inc.

Zitieren

APA

Murphy, M. B., Vitale, L., Xia, S., Peng, Z., O’Neill, T., Lillquist, J., Wasiuk, A., Weidlick, J., Widger, J., Mills-Chen, L., Crocker, A., Patterson, C., Boyer, J., Baronas, A. R., Chen, M., Davis, H. M., Ma, M., Goldstein, J., Thomas, L. J., …, & Keler, T. (2023). CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways. Immuno, 3(3), 273-288. https://doi.org/10.3390/immuno3030018

Vancouver

Murphy MB, Vitale L, Xia S, Peng Z, O’Neill T, Lillquist J, et al. CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways. Immuno. 2023;3(3):273-288. doi:10.3390/immuno3030018

BibTeX
@article{Murphy2023,
  author = {Murphy, Michael B. and Vitale, Laura and Xia, Shukai and Peng, Zeyu and O’Neill, Thomas and Lillquist, Jay and Wasiuk, Anna and Weidlick, Jeff and Widger, Jenifer and Mills-Chen, Laura and Crocker, Andrea and Patterson, Colleen and Boyer, James and Baronas, April R. and Chen, Mingjiu and Davis, Hugh M. and Ma, Mark and Goldstein, Joel and Thomas, Lawrence J. and Alvarado, Diego and Marsh, Henry C. and Keler, Tibor},
  title = {CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways},
  journal = {Immuno},
  year = {2023},
  volume = {3},
  number = {3},
  pages = {273--288},
  doi = {10.3390/immuno3030018}
}
Kostenlos starten →